[Current state and perspectives of pharmacological and non-pharmacological treatment of atrial fibrillation: overview].
Okumura
Ken
K
okumura@cc.hirosaki - u.ac.jp
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000925:Anticoagulants / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000097:blood / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D001562:Benzimidazoles; D017115:Catheter Ablation; D000069604:Dabigatran; D015195:Drug Design; D005343:Fibrinolytic Agents; D006801:Humans; D019934:International Normalized Ratio; D011725:Pyridines; D014859:Warfarin / Q000008:administration & dosage
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran